<div><div></div><div>Sonoma Pharmaceuticals entered into an underwriting agreement with Dawson James Securities to complete a public offering of 2,962,962 units at $1.35 per unit. The underwriter's 45-day over-allotment option was fully exercised, and the offering closed April 27–28, 2026. Sonoma sold 1,650,716 common shares, 1,312,247 pre-funded warrants, and 3,407,404 common warrants, yielding approximately $3.5 million in net proceeds. The company also signed warrant agency agreements with Computershare and Computershare Trust Company to administer the offering's pre-funded and common warrants.Agreement 1: Sonoma Pharmaceuticals Prices $1.35 Unit Offering, Nets ~$3.5M Under Underwriting With Dawson James<ul><li>Agreement type: Underwriting agreement for public equity offering</li><li>Counterparty: Dawson James Securities</li><li>Signed / Effective: Apr 24 2026 / Apr 24 2026</li><li>Duration / Termination: Offering period; 45-day over-allotment; 90-day lock-up</li><li>Reason: Raise equity capital and enhance liquidity</li></ul>Agreement 2: Sonoma Pharmaceuticals Appoints Computershare as Warrant Agent for Offering Warrants<ul><li>Agreement type: Warrant agency agreements for pre-funded and common warrants</li><li>Counterparty: Computershare; Computershare Trust Company</li><li>Signed / Effective: Apr 28 2026 / Apr 28 2026</li><li>Duration / Termination: Through warrant expirations (up to 5 years)</li><li>Reason: Administer warrant issuance and exercises from the offering</li></ul>Original SEC Filing: Sonoma Pharmaceuticals, Inc. [ SNOA ] - 8-K - Apr. 30, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

SNOA

SBIO

LABU

Sonoma Pharmaceuticals has completed a public offering of 2,962,962 units at $1.35 each, netting approximately $3.5 million. The offering, underwritten by Dawson James Securities, included 1,650,716 common shares, 1,312,247 pre-funded warrants, and 3,407,404 common warrants. The offering closed on April 27-28, 2026, with a fully exercised 45-day over-allotment option. Sonoma also appointed Computershare as the warrant agent for the offering's warrants, effective April 28, 2026.

TradingView

Sonoma Pharma

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

Computershare Limited

Sonoma Pharmaceuticals Prices $1.35 Unit Offering, Nets ~$3.5M Under Underwriting With Dawson James